(866) 389-4659
Newsroom

Newsroom

Breakthroughs, milestones, and the science shaping the future of cord blood medicine.

All Coverage

Clinical Research

Long COVID Trial Shows 85% Fatigue Resolution with Cord Blood Therapy

Phase II results demonstrate significant improvement in post-COVID fatigue using REGENECYTE® cord blood infusion.

January 2026
Regulatory

FDA Grants Expanded Access for REGENECYTE® in Long COVID

Treatment now available outside of clinical trial settings.

2026
Award

Taiwan BIO Award for Innovation of the Year

Recognized for advancing cord blood therapies and global clinical impact.

2025
Recognition

Honored at Taiwan Presidential Office

Leadership recognized for contributions to stem cell science and cross-Pacific collaboration.

2025
Regulatory

FDA RMAT Designation for Long COVID

Regenerative Medicine Advanced Therapy designation accelerates the development pathway.

2024
Milestone

REGENECYTE® Receives FDA Biologics License

US License 2280 marks full FDA licensure for StemCyte's cord blood product.

2024
Research

Toward an HIV Cure: Case Published in Cell

The “New York Patient” achieves HIV-1 remission and possible cure following a CCR5Δ32 haplo-cord transplant.

2023